Gruss & Co. LLC Invests $130,000 in Bausch + Lomb Corporation $BLCO

Gruss & Co. LLC acquired a new position in shares of Bausch + Lomb Corporation (NYSE:BLCO) in the second quarter, Holdings Channel reports. The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $130,000. Bausch + Lomb accounts for about 0.6% of Gruss & Co. LLC’s holdings, making the stock its 20th largest holding.

A number of other large investors also recently bought and sold shares of the stock. Tabor Asset Management LP purchased a new position in Bausch + Lomb during the first quarter worth about $338,000. Allianz Asset Management GmbH acquired a new stake in Bausch + Lomb in the 1st quarter valued at approximately $4,712,000. TD Asset Management Inc acquired a new stake in Bausch + Lomb in the 1st quarter valued at approximately $588,000. Clark Estates Inc. NY raised its position in Bausch + Lomb by 3.7% in the first quarter. Clark Estates Inc. NY now owns 622,000 shares of the company’s stock valued at $9,019,000 after purchasing an additional 22,000 shares during the period. Finally, Alberta Investment Management Corp lifted its stake in Bausch + Lomb by 8.6% during the first quarter. Alberta Investment Management Corp now owns 3,266,193 shares of the company’s stock worth $47,360,000 after purchasing an additional 258,000 shares in the last quarter. Institutional investors and hedge funds own 11.07% of the company’s stock.

Bausch + Lomb Stock Performance

NYSE:BLCO opened at $14.94 on Friday. Bausch + Lomb Corporation has a 12 month low of $10.45 and a 12 month high of $20.89. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.51 and a quick ratio of 0.98. The firm has a market capitalization of $5.29 billion, a PE ratio of -17.17, a price-to-earnings-growth ratio of 1.69 and a beta of 0.63. The business’s fifty day moving average price is $15.00 and its 200 day moving average price is $13.59.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings data on Wednesday, October 29th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.02. Bausch + Lomb had a positive return on equity of 2.42% and a negative net margin of 6.13%.The business had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.28 billion. During the same period in the prior year, the firm posted $0.13 EPS. The business’s quarterly revenue was up 7.1% compared to the same quarter last year. Bausch + Lomb has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Bausch + Lomb Corporation will post 0.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BLCO. JPMorgan Chase & Co. boosted their price objective on Bausch + Lomb from $13.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday. Barclays increased their price target on shares of Bausch + Lomb from $16.00 to $17.00 and gave the stock an “equal weight” rating in a research report on Friday. Citigroup restated a “neutral” rating on shares of Bausch + Lomb in a report on Tuesday, October 7th. Wells Fargo & Company increased their target price on shares of Bausch + Lomb from $15.00 to $16.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, Morgan Stanley boosted their price target on shares of Bausch + Lomb from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, August 1st. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $16.33.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.